Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-28

FDA Approved: RELAFEN DS — Supplemental Application (Carwin Pharmaceutical Associates, LLC)

View source ↗

Summary

FDA approved a supplemental application for Relafen DS (nabumetone) submitted by Carwin Pharmaceutical Associates, LLC. Nabumetone is used to treat symptoms of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RELAFEN DS (nabumetone)

Snippet

SUPPL AP for RELAFEN DS (NABUMETONE)